{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-008318","form_type":"8-K","ticker":"APVO","cik":"0001671584","company_name":"Aptevo Therapeutics Inc.","filed_at":"2026-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.840555+00:00","generated_at":"2026-05-16T11:04:20.757880+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aptevo secures $60M equity line with Yorkville, extends funding runway into 2029","bullets":["Enters $60M Standby Equity Purchase Agreement with Yorkville; minimal fees, no warrants.","Company has right to sell shares at 96% of lowest 3-day VWAP; capped at ~199,466 shares without approval.","Fully leveraged facility plus cash on hand expected to extend funding into 2029.","Proceeds to support pipeline including mipletamig (CD123xCD3) in Phase 1b/2 frontline AML trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-008318","json":"https://secwatch.observer/filing/0001193125-26-008318.json","markdown":"https://secwatch.observer/filing/0001193125-26-008318.md","text":"https://secwatch.observer/filing/0001193125-26-008318.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671584/000119312526008318/0001193125-26-008318-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671584/000119312526008318/apvo-20260108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:04:20.757880+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e4ef4a8a5e50e1385a99a0313bf4be0dac6c4d0e","claim":"Aptevo Therapeutics Inc. entered into Standby Equity Purchase Agreement with YA II PN, LTD. valued at up to $60.0 million (effective 2026-01-08).","evidence_excerpt":"On January 8, 2026, Aptevo Therapeutics Inc. (the \"Company\") entered into a Standby Equity Purchase Agreement (the \"Purchase Agreement\") with YA II PN, LTD., a Cayman Islands exempt limited company (\"Yorkville\"). Pursuant to the Purchase Agreement, the Company has the right, but not the obligation, to issue and sell to Yorkville from time to time (each such occurrence, an \"Advance\") up to $60.0 million (the \"Commitment Amount\") of the Company's common stock","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671584/000119312526008318/0001193125-26-008318-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"YA II PN, LTD."},{"label":"Value","value":"up to $60.0 million"},{"label":"Effective","value":"2026-01-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}